摘要
目的分析重组人干扰素α-2b联合恩替卡韦对慢性乙型肝炎患者免疫功能的影响。方法选取2016年1月—2018年1月济源市人民医院收治的慢性乙型肝炎患者95例为研究对象,根据入院顺序随机将其分为对照组和观察组,对照组49例患者给予恩替卡韦进行治疗,观察组46例患者给予重组人干扰素α-2b联合恩替卡韦进行治疗,两组患者均治疗3个月。对比两组患者的临床疗效、免疫功能变化及不良反应情况。结果观察组治疗总有效率为89.13%,对照组治疗总有效率为77.55%,观察组显著高于对照组(P<0.05)。治疗前,两组患者的CD4^+、CD8^+、CD4^+/CD8^+、C3、C4水平均无统计学差异;治疗后,对照组CD4^+、CD8^+、CD4^+/CD8^+水平与治疗前比较差异不显著;观察组患者的CD4^+、CD4^+/CD8^+水平均显著升高,CD8^+水平显著降低(P<0.05);治疗后,两组C3、C4水平均显著高于治疗前(P<0.05);且观察组患者的C3、C4水平均显著高于对照组(P<0.05)。观察组不良反应总发生率为23.91%,与对照组不良反应总发生率24.49%比较,差异无统计学差异。结论重组人干扰素α-2b联合恩替卡韦治疗慢性乙型肝炎的效果显著,该方法可有效改善患者的免疫功能、且不良反应未增加,临床应用价值较高。
Objective To analyze the effect of pegylated interferon alfa-2 b plus entecavir on immune function in patients with chronic hepatitis B.Methods We selected 95 patients with chronic hepatitis B treated in our hospital between January 2016 and January 2018 as subjects.According to the order of admission,they were randomly divided into a control group of 49 patients(treated with entecavir)and a study group of 46 patients(treated with pegylated interferon alfa-2 b plus entecavir).The treatment effect of the two groups of patients was compared.Results The total effective rate of treatment in the study group was(89.13%)significantly higher than that of the control group(77.55%)(P<0.05).Before treatment,there was no significant difference in the levels of CD4^+,CD8^+,CD4^+/CD8^+,C3,and C4 between the two groups.After treatment,the levels of CD4^+,CD8^+,and CD4^+/CD8^+in the study group were significantly lower than those in the treatment group(P<0.05);C3 and C4 levels in study group were significantly lower than before treatment and control group(P<0.05).The incidence of adverse reactions in the study group was 23.91%,and 24.49%in the control group was not statistically different.Conclusions The effect of pegylated interferon alfa-2 b combined with entecavir in the treatment of chronic hepatitis B is significant.This method can effectively improve the patient’s immune function and does not increase the adverse reactions.The clinical application value is high.
作者
梁超
毛重山
闫宏宪
LIANG Chao;MAO Chongshan;YAN Hongxian(Infection Department,Jiyuan City People's Hospital of Henan Province,Jiyuan 454651,China;Infection Department,Henan Provincial People's Hospital,Zhengzhou 450003,China;Hepatological Surgery Department,Henan Provincial People's Hospital,Zhengzhou 450003,China)
出处
《药物评价研究》
CAS
2019年第5期967-969,共3页
Drug Evaluation Research
